Does Rallies show Form 4 insider transactions for OPRX?

Yes. Rallies tracks OPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OPRX. It does not provide personalized investment advice.

OPRX (OptimizeRx Corporation Common Stock) Stock Analysis - Insider Trades

OptimizeRx Corporation Common Stock (OPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, OPRX trades at $5.24 with a market cap of $95.51M and a P/E ratio of 17.54. OPRX moved +3.00% today. Year to date, OPRX is -62.26%; over the trailing twelve months it is -58.41%. Its 52-week range spans $3.78 to $22.25. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces OPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OPRX stock inside the company?

Recent OPRX insider activity includes Stelmakh Edward sold 1.39K, Silvestro Stephen L sold 1.62K, Spangler Patrick D sold 11.12K, and Lang James Paul bought 321.41K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OPRX Key Metrics

Key financial metrics for OPRX
Metric	Value
Price	$5.24
Market Cap	$95.51M
P/E Ratio	17.54
EPS	$0.28
Dividend Yield	0.00%
52-Week High	$22.25
52-Week Low	$3.78
Volume	1.04K
Avg Volume	0
Revenue (TTM)	$109.43M
Net Income	$5.13M
Gross Margin	67.25%

Recent OPRX Insider Trades

Stelmakh Edward sold 1.39K (~$18.75K) on Dec 19, 2025.
Silvestro Stephen L sold 1.62K (~$30.38K) on Oct 3, 2025.
Spangler Patrick D sold 11.12K (~$194.49K) on Aug 28, 2025.
Lang James Paul bought 321.41K (~$2.44M) on Mar 14, 2025.

Latest OPRX News

OptimizeRx Taps DSPs for Programmatic EHR Ads, Targets $19B Pharma Market — May 13, 2026
OptimizeRx Posts Double-Digit AI Engagement Growth, Revenue Slips in Q1 — May 13, 2026
OptimizeRx Narrows Q1 Loss and Raises 2026 Revenue Guidance to $95-$100M — May 12, 2026
OptimizeRx Enables DSPs to Tap 90% U.S. Digital Display Ad Spend — May 11, 2026
OptimizeRx Appoints Microsoft Health COO Mary Varghese Presti to Drive Subscription Revenue — Apr 8, 2026

OPRX Analyst Consensus

6 analysts cover OPRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.

Common questions about OPRX

Who is trading OPRX stock inside the company?: Recent OPRX insider activity includes Stelmakh Edward sold 1.39K, Silvestro Stephen L sold 1.62K, Spangler Patrick D sold 11.12K, and Lang James Paul bought 321.41K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OPRX?: Yes. Rallies tracks OPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OPRX. It does not provide personalized investment advice.